Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420873 | 0.83 | MAOB (0.60) | MAOBHTR6PRMT5NR4A2MAOA | |
| Hydrochloric Acid SCHEMBL2198299 | 0.82 | MAOB (0.59) | MAOBHTR6PRMT5MAOA | |
| SCHEMBL12420762 | 0.79 | NR4A2 (0.55) | MAOBPRMT5NR4A2PARP10MAOA | |
| SCHEMBL12420601 | 0.79 | NR4A2 (0.62) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL1532668 | 0.79 | ALDH1A1 (0.53) | MAOBHTR6PRMT5NR4A2PARP10 | |
| Hydrochloric Acid SCHEMBL2195211 | 0.78 | NR4A2 (0.60) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL15171108 | 0.77 | MAOB (0.73) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL27521276 | 0.76 | MAOB (0.77) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL1532769 | 0.76 | MAOB (0.59) | MAOBHTR6PRMT5NR4A2PARP10 | |
| SCHEMBL12420658 | 0.76 | MAOB (0.56) | MAOBHTR6NR4A2PARP10SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | MAOB 222/4885HTR6 3435/4885PRMT5 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.